BRCA1 and neoplasm: This is the case with tumours associated with mutations in one copy of either BRCA1 or BRCA2; in these tumours, PARP1/2 inhibitors lead to an accumulation of DNA SSBs, which are converted during replication to irreparable toxic DNA double-strand breaks [3,4].